Core Insights - China Biopharmaceutical (01177) announced the presentation of four research results for its developed products at the 2025 European Respiratory Society Annual Meeting (ERS 2025) scheduled from September 27 to October 1 [1] Group 1 - The products to be presented include "TQC3721 (PDE3/4 inhibitor)", "TQC2731 (TSLP monoclonal antibody)", and "TQC3403 (Umeclidinium/Vilanterol inhalation powder)" [1]

智通财经APP讯，中国生物制药(01177)公布，集团开发的"TQC3721 (PDE3/4抑制剂)"、"TQC2731 (TSLP单抗)"、"TQC3403 (乌美溴铵维兰特罗吸入粉雾剂)"将于9月27日至10月1日举行的2025年欧洲呼 吸学会年会 (ERS 2025)公布4项研究成果。 ...

「TQC3721 (PDE3/4抑制劑）」、「TQC2731 (TSLP單抗）」、「TQC3403 (烏美溴銨維蘭 特羅吸入粉霧劑)」共4項研究數據在ERS 2025公布 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團開 發的「TQC3721 (PDE3/4抑制劑）」、「TQC2731 (TSLP單抗）」、「TQC3403 (烏美溴銨維蘭特羅吸入粉 霧劑)」將於9月27日至10月1日舉行的2025年歐洲呼吸學會年會 (ERS 2025）公布4項研究成果。 TQC3721 (PDE3/4抑制劑） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQC2731 (TSLP單抗） TQC3721是一款全新機制的吸入性PDE3/4抑制劑，具有擴張支氣管和抗炎的雙重作用，從而減 輕患者症狀並抑制炎 ...

Investment Rating - The industry rating is "Outperform the Market" [4] Core Insights - The domestic Big Pharma companies have shown impressive mid-year performance, with significant contributions from innovative drug businesses driving revenue growth [2] - The report highlights the successful transformation of traditional pharmaceutical companies towards innovation, with overseas collaboration and licensing deals enhancing their financial performance [2] - The report emphasizes the importance of the biopharmaceutical industry as a strategic emerging industry, with government support for high-quality technological supply and policy backing [2] Summary by Sections Industry Performance - The SW Pharmaceutical and Biotech Index increased by 1.05%, underperforming the CSI 300 Index which rose by 4.18% during the week [2] - Medical device and vaccine sectors showed relative gains, while CXO sector experienced a decline of 3.00% [2] Company Highlights - Heng Rui Medicine reported a revenue of 15.761 billion yuan, a year-on-year increase of 15.88%, with innovative drug sales contributing 7.570 billion yuan, accounting for 54.97% of product sales [2] - China Biopharmaceutical achieved a revenue of 17.575 billion yuan, a 10.71% increase, with innovative drugs contributing 7.800 billion yuan, a growth of 27.2% [2] Policy and Market Trends - The approval of the Jiangsu Free Trade Zone biopharmaceutical development plan aims to create a globally influential biopharmaceutical industry cluster [2] - The report suggests that the positioning of the pharmaceutical industry has evolved from a "livelihood project" to a "new productive force," highlighting the significance of innovative drug exports [2] Investment Strategy - The report identifies three main investment themes: 1. Focus on innovative drug exports, particularly in ADC, PD-1 bispecific antibodies, and weight-loss drugs [2] 2. High-growth CXO sector leaders [2] 3. Revaluation of Big Pharma pipelines [2] - The report maintains a bullish outlook on the pharmaceutical technology market for the year, emphasizing the importance of upcoming academic conferences and national health insurance negotiations [2]

招商证券国际发表研报指，中国生物制药上半年收入按年增10%，达176亿元，超预期。管理层指引下 半年增长提速，该行预计公司2026及27年将恢复双位数增长，又认为呼吸系统及肝病领域的增长潜力被 市场低估，因公司有更优的增长前景与丰富的商业发展(BD)机会，将公司目标价上调至9.8港元，维 持"增持"评级。 该行对中生制药持乐观看法，认为其作为行业领导者受益于肿瘤及外科、镇痛药物的强劲表现，以及集 中采购政策稳定对均价的负面影响减弱。公司过去通过有效的资产处置，重新聚焦四大治疗领域，该行 预计这将提升整体的经验效率和质量。 ...

招商证券国际发表研报指，中国生物制药上半年收入按年增10%，达176亿元，超预期。管理层指引下 半年增长提速，该行预计公司2026及27年将恢复双位数增长，又认为呼吸系统及肝病领域的增长潜力被 市场低估，因公司有更优的增长前景与丰富的商业发展(BD)机会，将公司目标价上调至9.8港元，维 持"增持"评级。该行对中生制药持乐观看法，认为其作为行业领导者受益于肿瘤及外科、镇痛药物的强 劲表现，以及集中采购政策稳定对均价的负面影响减弱。公司过去通过有效的资产处置，重新聚焦四大 治疗领域，该行预计这将提升整体的经验效率和质量。 ...

Core Viewpoint - The Chinese innovative drug industry is rapidly developing under policy support and globalization, with leading companies like BeiGene and HengRui Medicine making significant advancements through high R&D investments and dense pipelines [2][3]. Policy and Market Dynamics - The National Healthcare Security Administration initiated the 2025 medical insurance directory adjustment, emphasizing support for innovative drugs, which has boosted industry confidence [3]. - In the first half of 2025, the transaction amount for Chinese innovative drug BD reached $48.448 billion, highlighting accelerated globalization and international cooperation [3]. Company Performance Overview - **BeiGene**: Achieved revenue of 17.518 billion yuan, a 46% increase year-on-year, with a net profit of 450 million yuan, marking its first profitable half-year since listing. Its core product, Tislelizumab, generated sales of 2.643 billion yuan, up 20.6% [7]. - **HengRui Medicine**: Reported innovative drug sales and licensing income of 9.561 billion yuan, accounting for 60.66% of total revenue, with core innovative drug sales driving growth [8]. - **Hansoh Pharmaceutical**: Revenue reached 7.434 billion yuan, a 14.3% increase, with innovative drug sales contributing 82.7% [8]. - **Innovent Biologics**: Generated over 5.2 billion yuan in product revenue, a growth of over 35%, and completed a significant financing project [8]. - **China National Pharmaceutical Group**: Revenue of 17.57 billion yuan, with a net profit of 3.39 billion yuan, a 140.2% increase year-on-year [8]. - **East China Pharmaceutical**: Achieved revenue of 7.317 billion yuan, a 9.24% increase, with R&D investment rising significantly [9]. R&D Pipeline and Trends - The innovative drug sector is experiencing a concentrated R&D phase, with leading companies accelerating their pipeline development [10]. - **HengRui Medicine**: Six first-class innovative drugs were approved during the reporting period, with a robust pipeline including multiple drugs in various clinical stages [13]. - **BeiGene**: Continues to advance in ADC and bispecific antibodies, enhancing its international competitiveness [13]. - **Innovent Biologics**: Has 52 drugs in clinical stages, focusing on various innovative targets [13]. Role of Scientific Instrumentation - Scientific instrument manufacturers are transitioning from supporters to key enablers in the innovative drug sector, providing comprehensive technical support throughout the drug development process [3][14]. - **Waters Corporation**: Reported an 11% growth in pharmaceutical business, with a 70% increase in GLP-1 related income [15]. - **Agilent Technologies**: Increased revenue in life sciences and diagnostics, establishing strategic partnerships to enhance drug development capabilities [16]. - **Thermo Fisher Scientific**: Achieved $6 billion in laboratory product sales, exceeding market expectations, and providing comprehensive services for drug development [16]. Industry Outlook - The rapid development of new molecular types like antibodies and ADCs is creating significant challenges in quality management, fostering a deep coupling between innovative drug companies and scientific instrument manufacturers [18].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [5] Core Viewpoints - Traditional pharmaceutical companies have shown impressive mid-year results, with significant progress in innovation transformation. The innovation revenue is becoming a key driver for high growth in performance [4][9] - The report emphasizes the importance of innovative drugs as a stable industry trend, highlighting several key companies in both A-shares and Hong Kong stocks that are expected to perform well [5][6] - The report suggests that the pharmaceutical sector is well-positioned for growth in 2025, driven by factors such as the aging population, improved overseas capabilities, and advancements in AI technology [5][6] Summary by Sections Industry Performance - From August 18 to August 22, the pharmaceutical index rose by 1.05%, underperforming the CSI 300 index by 3.13%. Notable gainers included companies like Olin Bio and Furuida [6][44] - A total of 313 stocks in the pharmaceutical sector rose, while 171 fell during the same period [6][44] Company Highlights - **Hengrui Medicine**: Reported revenue of 15.761 billion RMB for H1 2025, a year-on-year increase of 15.88%. The net profit was 4.450 billion RMB, up 29.67%. Innovative drug sales reached 7.570 billion RMB, growing by 21.80% [10][15] - **Hansoh Pharmaceutical**: Achieved revenue of 7.434 billion RMB in H1 2025, a 14.3% increase. The net profit was 3.135 billion RMB, up 15.0%. Innovative drug sales accounted for 82.7% of total revenue [21][28] - **China National Pharmaceutical Group**: Reported revenue of 17.57 billion RMB for H1 2025, a 10.7% increase, with a net profit of 3.39 billion RMB, up 12.3%. Innovative revenue reached 7.8 billion RMB, growing by 27.23% [34][35] Investment Recommendations - The report recommends focusing on innovative drugs, manufacturing overseas, and addressing the needs of an aging population. Specific stocks to watch include Xintai, Shanghai Yizhong, and Hengrui Medicine [5][6][44] - The report highlights the potential for valuation recovery in relatively undervalued pharmaceutical assets [5][6]

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, anticipating a reversal in the market by 2025, with innovative drugs and the recovery of left-side sectors being the main investment opportunities [5][13]. Core Views - The report highlights that major domestic pharmaceutical companies have stabilized their revenues after previous disruptions from centralized procurement, with visible results from their innovation transformations [2][12]. - It emphasizes the importance of BD (business development) collaborations, citing significant deals involving major multinational pharmaceutical companies, which could lead to sustainable income for companies like Heng Rui Medicine [2][12]. - The report suggests focusing on innovative drugs, particularly dual/multi-target antibodies and drugs addressing unmet clinical needs, as key investment opportunities [3][5][13]. Summary by Sections Pharmaceutical Sector - The innovative drug market is experiencing adjustments, but the overall policy environment remains supportive for innovation [3]. - After ten rounds of centralized procurement, the risks for leading pharmaceutical companies are gradually being alleviated, revealing competitive innovative drug pipelines [3][22]. - The report recommends paying attention to leading pharmaceutical companies' transformation results and overseas opportunities [3][5]. Biopharmaceuticals - Jin Sai Pharmaceutical's dual-target ADC GenSci143 has received IND approval, showing potential as a leading treatment option for prostate cancer and other solid tumors [3][41][46]. Medical Devices - The registration and promotion of innovative products in the domestic medical device sector are accelerating, contributing to long-term high-quality development [4][47]. - Companies like Huitai Medical have reported significant revenue growth, with innovative products rapidly expanding their market presence [4][47][48]. Traditional Chinese Medicine - Some companies are facing performance pressure during the destocking cycle, but strong brands like Dong'e Ejiao continue to achieve resilient growth [4][54][56]. Investment Recommendations - The report suggests focusing on innovative drugs, particularly in the fields of dual/multi-target antibodies and drugs for chronic diseases, as well as opportunities in ADC and small nucleic acid sectors [5][13]. - The medical device sector is expected to see a significant performance turnaround in the second half of the year, driven by favorable policies and recovering tender trends [5][13]. Key Targets - Notable companies to watch include Innovent Biologics, Kintor Pharmaceutical, and Heng Rui Medicine, among others [6].

Core Insights - The domestic pharmaceutical M&A market is experiencing increased activity, with notable transactions such as Shandong Keyuan Pharmaceutical's plan to acquire 99.42% of Shandong Hongjitang Pharmaceutical for approximately 3.581 billion yuan and Yunnan Baiyao's acquisition of 100% of Juyatang Pharmaceutical for 660 million yuan [1][2] - Despite the uptick in transaction amounts, the overall number of M&A deals in the pharmaceutical sector has decreased compared to last year, with 195 deals reported this year, down from 229 [1] - The total value of M&A transactions in the pharmaceutical sector has reached 21.447 billion yuan this year, more than double the amount from the same period last year [1] M&A Market Dynamics - The pharmaceutical sector is not currently a hot area for M&A, with more focus on sectors like semiconductors and new energy [2] - The success rate for M&A exits in the pharmaceutical sector is low, with only 4 out of 200 projects successfully exiting through M&A, indicating a success rate of 1 in 50 [2] - Price consensus is a significant challenge in pharmaceutical M&A, with varying valuations complicating negotiations [2] Case Studies - A notable case is the acquisition of Kanglu Biological by Tsinghua Tongfang, where the deal involved differentiated pricing for different rounds of investors, highlighting the complexities of M&A transactions [3][4] - The acquisition of Lixin Pharmaceutical by China National Pharmaceutical Group for up to $950 million is highlighted as the largest acquisition in the sector this year, with a valuation that tripled in less than a year [6][7] - Lixin Pharmaceutical's strong financial position, including a $588 million upfront payment from Merck for a drug licensing agreement, underscores its market potential [6][8] Future Outlook - The recent surge in business development (BD) transactions indicates a shift in the pharmaceutical M&A landscape, with over 50 outbound transactions totaling more than $48 billion in the first half of the year [9][10] - The entry of international buyers and the restructuring of valuation systems may lead to increased M&A activity in the future, particularly as domestic pharmaceutical companies grow in value [10] - The potential for significant M&A activity is anticipated as the industry evolves, with a need for technological integration among larger pharmaceutical firms [10]